Novartis initiates Phase Ib/II study of AMO959 in mCRPC with AAA617 and ARPI
Novartis is conducting Phase Ib/II study to evaluate AMO959 combined with AAA617 and ARPI in mCRPC patients.
Asset / Drug
Drug and asset intelligence for AMO959 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.